Key insights
- Abbott Laboratories (ABT) stock hit a 52-week low, down over 20% year-to-date, reflecting market pressures despite a history of dividend payments. The acquisition of Exact Sciences, while boosting sales potential, is expected to dilute EPS. Analyst ratings remain largely positive, citing growth in structural heart and diabetes care segments. The stock's current weakness, despite positive analyst outlooks and strategic acquisitions, suggests near-term headwinds for the healthcare giant, potentially impacting investor sentiment in the broader healthcare sector.
Abbott Laboratories stock has reached a 52-week low, trading at $100.85. This milestone marks a significant downturn for the $175.86 billion healthcare giant, reflecting a challenging year with a 1-year change of -20.39%. Despite the decline, InvestingPro analysis suggests the stock appears undervalued at current levels, with the company maintaining its dividend for 56 consecutive years—a testament to financial resilience. The stock’s decline over the past year underscores the pressures facing Abbott Laboratories in a competitive market environment. With earnings scheduled for April 16, investors seeking deeper insights can access Abbott’s comprehensive Pro Research Report, one of 1,400+ available on InvestingPro, which transforms complex Wall Street data into actionable intelligence.
In other recent news, Abbott completed its acquisition of Exact Sciences, enhancing its cancer screening and diagnostics capabilities. This merger makes Exact Sciences a wholly owned subsidiary of Abbott, with the transaction expected to contribute approximately $3 billion in incremental sales by 2026. Despite this positive outlook, the acquisition is projected to dilute Abbott’s 2026 adjusted earnings per share by about $0.20. Additionally, Abbott has integrated its Precision Oncology test portfolio into Flatiron Health’s OncoEMR platform, streamlining the process for oncology providers to order tests and receive results.
In analyst updates, UBS reiterated a Buy rating on Abbott Laboratories, highlighting potential growth in Abbott’s structural heart business due to anticipated positive outcomes from the CHAMPION study. Benchmark also maintained a Buy rating, citing favorable results from the FreeDM trial, which demonstrated significant improvements in glucose outcomes for Type 2 diabetics using Abbott’s FreeStyle Libre technology. These developments reflect a series of strategic moves and positive evaluations by analysts, positioning Abbott for continued growth in its healthcare offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.